Modality
Bispecific Ab
MOA
FcRni
Target
PD-1
Pathway
Wnt
PSP
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
~Jan 2021
→ ~Apr 2022
Phase 3
Jul 2022
→ Nov 2028
Phase 3Current
NCT06140559
471 pts·PSP
2022-07→2028-11·Recruiting
471 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-252.7y awayPh3 Readout· PSP
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Recruit…
Catalysts
Ph3 Readout
2028-11-25 · 2.7y away
PSP
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06140559 | Phase 3 | PSP | Recruiting | 471 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Motanaritide | Intellia | Approved | PD-1 |